MDWD - MediWound's Late Stage Clinical Products Review Analysts Review and Target
NEW YORK, NY / ACCESSWIRE / January7, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds.
MediWound's first biopharmaceutical product, NexoBrid®, received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean and Russian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns.
Get the MDWD financial data, analysts report, target price and more READ MORE
Copyand paste to your browser may be required to view the report - https://tradersnewssource.com/mediwound/
According to management, MediWound was approached earlier this year by a third party to consider a potential strategic transaction. Subsequently, we engaged an investment bank to help us review the proposal and advise in our discussions. We commenced discussions, and thereafter, received approaches and engaged in discussions and diligence with other strategic parties on different strategic transaction scenarios.
They continue to be in discussions and diligence with a subset of those parties.
Reviewthe company pipeline and details about MDWD products here READ MORE
Copyand paste to your browser may be required to view the report - https://tradersnewssource.com/mediwound/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source